EUVIMEDEUVIMED entdecken
Crossref

Real-World Testing for Pathogenic BRCA1/2 Germline Variants in Breast Cancer in Germany

M P Lux, D Speiser, S Peinert, D Schmitt

Senologie - Zeitschrift für Mammadiagnostik und -therapie · 01.05.2026 · 23 (02) · e22

DOI: 10.1055/s-0046-1819786 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Senologie - Zeitschrift für Mammadiagnostik und -therapie, erschienen am 01.05.2026. Verfasst von M P Lux und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Pathogenic germline variants in BRCA1/2 (gBRCA1/2m) are therapeutically relevant in early breast cancer (eBC) and advanced/metastatic breast cancer (mBC). In HER2-negative breast cancer proof of gBRCA1/2m is a prerequisite for treatment with PARPi. This survey analyzes the extent to which German oncologists implement guideline recommendations for testing eBC and mBC patients for gBRCA1/2m in real-world practice.

Methods

Oncologists in certified breast cancer centers (including university hospitals), non-university hospitals, oncology practices, and medical care centers completed a questionnaire on gBRCA1/2m testing of breast cancer patients at their institution. Data were analyzed exploratorily and results stratified by institution type.

Results

Across institutions and disease stages, 73% of eligible patients were tested for gBRCA1/2m to assess potential therapeutic consequences. At least 80% of physicians know they are allowed to initiate gBRCA1/2m testing as part of treatment planning, regardless of family history, if therapeutically relevant. Among TNBC patients with stage IIIC–IV disease who had received first-line therapy, an average of 87% were tested for gBRCA1/2m . In HR+/HER2−mBC, 57% of patients receiving first-line therapy were tested for biomarkers (including gBRCA1/2m ). Tumor biology, family history, and treatment setting particularly influenced testing frequency.

Zitieren

APA

Lux, M. P., Speiser, D., Peinert, S., & Schmitt, D. (2026). Real-World Testing for Pathogenic BRCA1/2 Germline Variants in Breast Cancer in Germany. Senologie - Zeitschrift für Mammadiagnostik und -therapie, 23(02), e22. https://doi.org/10.1055/s-0046-1819786

Vancouver

Lux MP, Speiser D, Peinert S, Schmitt D. Real-World Testing for Pathogenic BRCA1/2 Germline Variants in Breast Cancer in Germany. Senologie - Zeitschrift für Mammadiagnostik und -therapie. 2026;23(02):e22. doi:10.1055/s-0046-1819786

BibTeX
@article{Lux2026,
  author = {Lux, M P and Speiser, D and Peinert, S and Schmitt, D},
  title = {Real-World Testing for Pathogenic BRCA1/2 Germline Variants in Breast Cancer in Germany},
  journal = {Senologie - Zeitschrift für Mammadiagnostik und -therapie},
  year = {2026},
  volume = {23},
  number = {02},
  pages = {e22},
  doi = {10.1055/s-0046-1819786}
}
Kostenlos starten →